Most studies on the interaction of irinotecan with UGT1A1 have focused on patients with colorectal cancer (CRC) receiving the FOLFIRI (irinotecan, fluorouracil, and leucovorin) regimen [28,29,30,31,32]. This evidence concerns the gene UGT1A1 and colorectal carcinoma.